CA : 5-10 M€
The management team, which is led by Claude Hennion, is also composed of Raphaël Bardonnet and Hervé Meslin.
Capital Croissance facilitated the exit of the thirty historic shareholders who had supported the company in its start-up and structuring phases. By becoming the new reference shareholder alongside the management team and Turenne Capital, Capital Croissance is helping management to pursue the development of the company, especially in the dental market and internationally, while continuing to invest in the innovations that have made the company successful.
BIOBank, which was founded in 1999, collects femoral heads from human donors undergoing hip arthroplasty and then turns them into virally inactivated and sterile bone grafts by using the Supercrit® process. This technology has received “process/product” authorisations issued by the ANSM (French National Drug Safety Agency). The bone grafts are then used in orthopaedic and dental surgery. Based in the Paris region, Biobank has become, in 10 years, one of the top three private players in orthopaedics and the leading player in dentistry.
Claude Hennion, Director: « My first meeting with the Capital Croissance team was characterised by them taking attentive note of our business, its originality (human bone grafts), its strengths and its difficulties. This created a climate of mutual confidence necessary to want to work together.
Capital Croissance conducted thorough due diligence, was able to solve the difficulties associated with the highly disperse capital structure due to past events, listened to the expectations of the management and understood the constraints and strengths of our business.
We have dealt with a remarkably cohesive, enthusiastic and experienced team, with responsive and constructive suggestions, which made us want to share our vision with them. We are therefore highly satisfied that, on the basis of mutual trust, Capital Croissance has decided to actively support us in our development. »